Natriuretic peptides as markers of cardiovascular disease. Their use in diagnosis, prognosis and therapy
DOI:
https://doi.org/10.31053/1853.0605.v60.n1.33763Palabras clave:
.Resumen
.
Descargas
Referencias
Arad M, Elazar E, Shotan A, Klein R and Rabinowlts B. Brain and atrial natriuretic peptides in patients wlth ischeniic heart clisease with and without heart failure. Caidiotogy 87: 12-17, 1996.
Biyan VM. Deslgn of minimum active fragments of blologlcally active peptides. Methods In Enzymology 202: 436-448, 1991.
Cheng y, Kazanagra R, Garcia A, Lenert L, Krlshnaswaniy P, Gardetto N, Clopton P and Maisel A. A rapid bedside test forB-type peptide predlcts treatment outcomes in patients aclmitted for decoinpensated heart failure: a pilot study. J Am Col¿ Cardiol 37: 386-391, 2001.
Dao g, Krishnaswarny P. Kazanegra R, Harrison A, Amirnovin R, Lenert L, Clopton P, Alberto J, Hiavin P and Malsel AS. Utillty of 8-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Col[ Cardiol 37: 379-385, 2001. .
Davidson NG, Coutie WJ and Struthers AD. N -terminal proatrial natriuretic peptide and brain natriuretic peptide are stable for up to 6 hours in whole blood in vitro lletter]. Circulat ion 91: 1276-1277, 1995.
Davis KM, Fish LC, Elahi D, Clark BA and Minaker KL. Atrial natriuretic peptide levels in the prechiction of congestive heart failure nisk in frail elderly. JAMA 267: 2625-2629, 1992.
de Boid AJ. Atnial natrluretic factor: a hormone produced by the heart. Science 230: 767-770, 1985.
S. de Boid AJ, Borenstein HB, Veress AT and Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardlal extracts in rats. Ly'eSci28: 89-94, 1981.
de Lenios JA, Morrow DA, Bentley JH, OmlandT, Sabatine MS, McCabe CH, Hall C, Cannon GP and Braunwald E. The prognostic value of B-type natriuretic peptide in patients with acute coronary synclromes. N Engl J Med 345: 1014-1021,2001.
Dickstein K, Larsen Al, Bonarjee V, Thoresen M, Aarsland T and Hall C. Plasma proatrial natriuretic factor is predictive of clinical status in patients with congestive heart failure. Am J Cardiol 76: 679-683, 1995.
Hall C, Aaberge L and Stokke O. In vitro stability of N-ten]i1na1 proatrial natrluretic factor in unfrozen samples: an important prerequisite for its use as a blochemical parameter of atrial pressure in clinical routine [letter]. Circu!aton9l: 911, 1995.
Hall O, Cannon CP, Forman S and Braunwald E. Prognostic value of N-terminal proatrial natrluretic factor plasma leveis measured within the first 12 hours after myocardlal lnfarction. J Am Co!! Carciiol 26(6): 1452-1456, 1995.
Hall C, Rouleau JL, Moyé L, de Champlain ,J, Bichet D, Klein M, Sussex B, Packer M, Rouleau J, Arnold MO, Lamas GA, Sestier F, Gottlieb SS, Wun O-CC and Pfefler MA. N-Terminal Proatrial Natriuretic Factor. Circu!a0on 89: 1934-1942, 1994.
Kazanegra R, Cheng V, Garcia A, Krlshnaswairiy P, Gardetto N, Clopton P and Maisel A. A rapid test for B-type natrluretic peptide correlates with failing wedge pressures in patients treated for decompensated heart failure: a i)llot study. J Card. Fail 7: 21-29, 2001.
Lerman A, Gibbons RJ, Rodeheffer R,J, Balley KR, McKinley U, Heublein DM and Burnett JO, Jr. Circulating N - terminal atrial natriuretic peptide as a marker for symptornless left-ventricular dysfunctlon [see comments]. Lancet 341: 1105-1109, 1993.
Lincoln TM and Cornwell TL. Intracellular cycllc GMP receptor prote!ns. FASEB J 7: 328-338, 1993.
Maekawa K, Sudoh T, Furusawa M, Minamino N, Kangawa K, Ohkuho H, Nakanishi S and Matsuo N. Cloning and sequence analysis of cDNA encoding a precursor for porcine brain natrlurettc peptide. Biochem Biophys Res Commun 157: 410-416, 1988.
Maisel A. B-type natrluretic peptide levels: a potential novel "white count" for congestive heart failure. J Card Fail 7: 183-193, 2001.
Maisel AS. Practical approaches to treattng patients wlth acute deconipensatecl heart failure. J Card Fail 7: 13-17, 2001. Maisel AS. Practica] approaches to treating patients with acute decompensated heart failure. J Card Pali 7: 13-17, 2001.
Masters RG, Davles RA, VeinotJP, Hendry PJ, Smith Si and de Boid AJ. Dlscoordinate Modulation of Natriuretic Peptides During Acute Cardlac Allograft Rejection in Hurnans. Circulation 100: 287-291, 1999.
Moe GW, Rouleau ,JL, Charbonneau L, Proulx G, Arnold JM, Hall O, de Chainplaln J, Barr A, Sirois P and Packer M. Neurohormonal activation In severe heart failure: relatlons to patient death and the effect of treatmenl with flosequinan. Am Heart J 2000 Apr 139 (4):587 -95 139: 587-595, 2000.
Motwani JG, McAlpine H, Kennedy N and Struthers AD. Plasma brain natrluretic peptide as an indicator for anglotensin- converting-enzyme inhibition after myocardial infarctlon. Lancet 341: 1109-1113, 1993.
Murakami Y, Shlmada T, lnoue S, Shlmjzu H, Ohta Y, Katoh H, Nakamura K and Ishibashi Y. New lnslghts Into the mechanism of the elevation of plasma brain natriuretic polypeptide levels In patients with left ventricular hypertrophy. Can J Cctrdiol 18: 1294-1300, 2002. Rlchards AM, Crozler IG, Yanclle TG, Espiner EA, lkram H and Nicho]ls MG. Brain natrluretic factor: regional plasma concentrations and correlations with haemodynamlc state in cardiac disease. Br Heart J 69: 414-417, 1993.
Taiwar S, Downle PF, Ng LL and Squire IB. Towards a blood test for heart failure: the potential use of clrculat!ng natriu re tic peptides. Br J Clin Pharmacol 50: 15-20, 2000.
Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholis MG and Richards AM. Treatment of heart failure guided by plasma arninoterminal brain natrluretic peptide (N-BNP) concentratlons. Lancet 355: 1126-1130, 2000.
Yokota N, Bruneau BG, Fernandez BE, Kuroskl de Bold ML, Piazza LA, Eicl FI and de Bo1dAJ. Dlssoclatlon of carcllac hypertrophy, myosin heavy chairi isoform expresslon, and natrluretic peptide production in DOCA-salt rats. Am J Hypef'tens8: 301-310, 1995.
Descargas
Publicado
Número
Sección
Licencia
Derechos de autor 2021 Universidad Nacional de Córdoba
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.
Se permite la generación de obras derivadas siempre que no se haga con fines comerciales. Tampoco se puede utilizar la obra original con fines comerciales.